Winston-Salem, NC, United States of America

Waldemar Debinski

This inventor holds 31 USPTO granted patents and 4 published patent applications and 4 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Wake Forest University, The Penn State Research Foundation, Virginia Tech Intellectual Properties Inc.. Active years: 2001-2026.

USPTO Granted Patents = 31 (Patent Applications = 4)

% Patents Active = 83.9

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 2.5

ph-index = 6

Forward Citations = 155(Granted Patents)

Location History:

Hershey, PA (US) (2001 - 2008)
Winston-Salem, NC (US) (2009 - 2024)
Blacksburg, VA (US) (2024)

Company Filing History:

22 out of 524

Wake Forest University

patents

9 out of 1,338

The Penn State Research Foundation

patents

1 out of 823

Virginia Tech Intellectual Properties Inc.

patents

where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

Cancer Immunotherapy

Multi-Level Targeting

Molecular Signature

IL-13

Antibodies

Tumor Targeting

Nucleic Acids

Fusion Protein

IL-13RA2

Cancer Cells

Peptides

Chimeric Molecules

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715926 - ANTIBODIES AGAINST HUMAN AND CANINE IL-13RA2 (2026-08-25),

2. 12419934 - Molecular signature of cancer (2025-09-23),

3. 12083339 - Induced cell morphology electroporation (2024-09-10),

4. 11976101 - Multi-level specific targeting of cancer cells (2024-05-07),

5. 11697675 - EPHA3 and multi-valent targeting of tumors (2023-07-11),

6. 11655299 - Antibodies against human and canine IL-13RA2 (2023-05-23),

7. 11207380 - Molecular signature of cancer (2021-12-28),

8. 11136367 - Multi-level specific targeting of cancer cells (2021-10-05),

9. 10752667 - EPHA3 and multi-valent targeting of tumors (2020-08-25),

10. 10676529 - Antibodies against human and canine IL-13RA2 (2020-06-09),

11. 10519210 - Multi-level specific targeting of cancer cells (2019-12-31),

12. 10233224 - Nucleic acids encoding a fusion protein useful for multi-level specific targeting of cancer cells (2019-03-19),

13. 9975942 - EPHA3 And multi-valent targeting of tumors (2018-05-22),

14. 9974830 - Molecular signature of cancer (2018-05-22),

15. 9878013 - IL-13 receptor binding peptides (2018-01-30),

Title: Waldemar Debinski: Pioneering Inventor from Winston-Salem

Introduction: Waldemar Debinski is a renowned inventor hailing from Winston-Salem, NC, known for his groundbreaking contributions to the field of medical technology.

Latest Patents: Waldemar Debinski holds several patents related to innovative cancer treatment methods and medical devices, with his most recent patent focusing on a novel targeted therapy for brain tumors.

Career Highlights: With a career spanning over two decades, Debinski has worked tirelessly to bridge the gap between scientific research and practical applications in the medical field. His work has significantly impacted the lives of patients worldwide.

Collaborations: Throughout his career, Waldemar Debinski has collaborated with leading research institutions, pharmaceutical companies, and medical professionals to further advance his inventions and bring them to market successfully.

Conclusion: Waldemar Debinski's dedication to innovation and his passion for improving healthcare have solidified his position as a pioneering inventor in the field of medical technology. His contributions continue to inspire future generations of inventors and researchers.